INTRODUCTION
1,2,4-oxadiazoles can be considered as bioisosters of amides and esters.
1a-c
Their biological importance is well documented.
2 Their properties make this class of compounds quite attractive to the pharmaceutical industry. Many articles indicate that a number of researchers, including those in our own group, have been trying to synthesize 1,2,4-oxadiazole with asymmetric center on the side-chain to improve the performance of these molecules as drugs. 3,4,1a,5a,b,6 In recent years, new methods have been used for the synthesis of 1,2,4-oxadiazole with one or more stereocenters. 7, 8 Thus, Porcheddu et al. 7 proposed a methodology for the synthesis of various disubstituted 1,2,4-oxadiazoles for the preparation of heterocycles with a stereocenter with 100% enantiomeric purity. Asymmetric reduction of prochiral ketones into chiral non-racemic secondary alcohols is a fundamental process in the synthesis of organic compounds of biological interest.
6,7 Though numerous chemical methodologies are known in the synthesis of these secondary chiral alcohols, difficulties still remain in attaining high yields with enantiomeric excess. 7 For example, the sodium borohydride (NaBH 4 ) reduction of ketones may apparently be promoted either by the electrophilic activation of the substrate or the nucleophilic activation of the reagent-or, of course, both. This, in fact, leads to a possible asymmetric variant of the borohydride reaction, catalysis by an optically active alcohol in an inert solvent. 8 Several oxidoreductases are capable of efficiently reducing ketones with a combination of co-factors such as NADPH or NADH. 9 The use of whole cells, such as in baker's yeast (Saccharomyces cerevisiae), for chiral reduction is economically attractive due to its availability, low cost and ease of handling and disposal. 9 Because of the great significance of 1,2,4-oxadiazoles, and in particular oxadiazoles containing stereocenter in their side-chain which are being synthesized, we focused our attention first on reducing the side-chain keto group to alcohol. In this paper, we report on a asymmetric reduction of 4-[3-(aryl)-1,2,4-oxadiazol-5-yl] butanones 4a-e using bakers' yeast. These alcohols were characterized and later on allowed to react with tri-O-acetyl-Dglucal to obtain 2,3-unsaturated O-glycosides.
EXPERIMENTAL

Instruments and reagents
Melting points were determined on using an Electrothermal digital melting point apparatus (model IA9100) and are uncorrected. IR spectra were recorded as KBr films on a Brucker IFFS66 series Fourier transform spectrophotometer. Specific rotations were measured with a Perkin-Elmer polarimeter model 241. NMR spectra were recorded with a Varian Unity Plus instrument (300/75 MHz for 1 H/ 13 C) spectrometer, using CDCl 3 as the solvent. Chemical shifts are reported in parts per million (ppm) downfield from an internal TMS (trimethylsilane) reference. Elemental analysis was performed with a Carlo Erba instrument model E-1110. Silica gel coated plates with a fluorescent indicator (PF 254 ) were used for thin-layer chromatography (TLC), and the spots were detected under ultraviolet light. The solvent system for running the TLC plates was a mixture of 1:9 ethyl acetate-dichlromethane. Silica gel 60 (230 -400 mesh) was employed for liquid chromatography. All commercially available reagents were used directly without purification unless otherwise stated. All the solvents used in reactions were distilled for purity.
General Procedure for the Synthesis of 4-[3-(aryl)-1,2,4-oxadiazol-5-yl]-butan-2-ones
The reaction of 1a-e was with levulinic acid 2 and conducted according to the method of Srivastava et al.
10,11
Synthesis of 4-[3-(aryl)-1,2,4-oxadiazol-5-yl]-butanols
In a shaker with suspension of baker´s yeast ( 50g ), and sucrose (12g) in deionized water (400 mL ) a solution of 4-[3-(aryl)-1,2,4-oxadiazol-5-yl]-2-butanones (1.30g, 6.01 mmol) was added. The suspension was shaken at room temperature and the reduction followed by TLC. After 72h, the product was extracted into ethyl acetate (3 x 100mL) followed by separation of the layers. The combined organic extracts were dried (Na 2 SO 4 ), filtered, and the solvent removed under vacuum. The crude product was purified immediately by chromatography over silica gel using hexane/ethyl acetate (8:2) producing chromatographically pure 5a-e (Figure 1 ). The details are given below. [3-phenyl-1,2,4-oxadiazol-5-yl]-2-butanol (5a) (m, 2H, H-2' and H-6'), 7.49-7.45 (m, 3H, H-3', H-4' and H-5'), 3.95 (m, 1H, H-8) 6.48; N, 12.70 Found: C, 65.12; H, 6.81; N, 2, 7.39-7.28 (m, 3H, H-2', H-3' and H-4'), 3.97 (m, 1H, H-8), 3.11 (t, 2H, J 7.5 Hz, H-6 and H-6"), 2.62 ( s, 3H, Ph-CH 3 ), 2.20 (s, 1H, OH), 2.03 (m, 2H, H, H-7 and H-7"), 1.28 (d, 3H, J 6.0 Hz, CH 3 );
4-
13 C NMR (CDCl 3 ): δ 179.2 ( C=N), 169.1 (C=N), 138.5 (C-1'), 131.7 (C-2'), 130.9 (C-3'), 130.3 (C-6'), 126.4(C-5'), 126.3(C-4'), 67.7( C-8), 60.8 (C-7), 35.6 (C-6), 23.8 (CH 3 ), 23.2 (Ph-CH 3 ). Anal. Calcd for (C 13 H 16 O 7 N 2 ): C, 67.22 H, 6.94; N, 12.06 Found: C, 67.12; H, 6.46; N, 2, , 6.94; N, 12.06 Found: C, 67.10; H, 6.48; N, 2, 
General Procedure for the Synthesis of (S)-1-methyl-[3-(aryl)-1,2,4-oxadiazol-5-yl]-propyl-4,6-di-O-acetyl-2,3-dideoxy-α-d-erythro-hex-2-enopyranosides (7a-e)
The reaction of 5a-e with compound 6 were conducted according to the method of Toshima et al.
12 Figure 2 .The details are given below.
(S)-1-Methyl- [3-(phenyl)-1,2,4-oxadiazol-5-yl] propyl -4,6-di-O-acetyl-2,3-dideoxy-α-d-eryhtro-hex-2-enopyranoside (7a) , 6.08; N, 6.50 Found: C, 61.59; H, 6.14; N, 6.36 .
(S)-Methyl- [3-(o-tolyl)-1,2,4-oxadiazol-5-yl] propyl 4,6-di-O-acetyl-2,3-dideoxy-α-d-erythro-hex-2-enopyranoside (7b) , 6.35; N, 6.30. Found: C, 62.26; H, 6.44; N, 6.22 .
(S)-Methyl- [3-(m-tolyl)-1,2,4-oxadiazol-5-yl] propyl 4,6-di-O-acetyl-2,3-dideoxy-α-d-erythro-hex-2-enopyranoside (7c) (S)-Methyl- [3-(p-bromophenyl)-1,2,4-oxadiazol-5-yl] propyl 4, [3-(aryl)-1,2,4-oxadiazol-5-yl]-propyl-4,6- 
1-(S)-Methyl-[3-(p-tolyl)-1,2,4-oxadiazol-5-yl] propyl 4,6-di-O-acetyl-2,3-dideoxy-α-d-erythro-hex-2-enopyranoside (7d):
H, 4.95; N, 5.50. Found: C, 51.58; H, 4.68; N, 5.19 .
X-ray single crystal structure determination
Single crystal X-ray diffraction data of the title compound were collected at room temperature on a Nonius BV diffractometer using Mo-Kα radiation (λ = 0.71073 Å) through the program COLLECT [19] . Details of the crystal structure of C 22 H 25 N 2 O 7 are listed in Table 1 . The crystal structure has been solved and refined in the triclinic symmetry, space group P-1, using the WINGX environment 
RESULTS AND DISCUSSION
Initially 4-[3-(aryl)-1,2,4-oxadiazol-5-yl]-butan-2-one was prepared by using an appropriate benzamidoxime or arylamidoxime and levulinic acid in the presence of DCC in methylene chloride to get O-acyl intermediates, which were cyclized to 1,2,4-oxadiazoles following the common procedure. 10, 11 The mechanism of formation of 1,2,4-oxadiazoles from amidoximes and an acid, employing DCC as a carbonyl group activator is straight forward. The first step is the intermediate 3a-e production followed by thermal cyclodehydration to generate 4a-e. 10, 11 The compounds 4-[3-(aryl)-1,2,4-oxadiazol-5-yl]-butan-2-one 4a-e were reduced by use of bakers' yeast under conventional conditions. 7 Optically active 4-[3-(aryl)-1,2,4-oxadiazol-5-yl]-2-butanols 5a-e is a useful intermediate for the synthesis of O-glycoside. Compounds 5a-e were used to carry out Ferrier's rearrangement.
12,13 Reaction of these alcohols individually with tri-O-acetyl-d-glucal 6 after short reaction times produced the corresponding alkyl 2,3-unsaturated glycosides 7a-e in good yields, with the α-anomer being the greater or the exclusive product (Scheme 1).
originally superimposed methylene and methine multiplets will begin to be resolved. The 1 H NMR spectra of 7a-e show chemical shifts at 1.24 ≤ d ≤ 1.26 ppm, respectively; as a doublet with a coupling constant 6.0 ≤ J ≤ 6.2 Hz, which is due to the methyl group of the aglycone. The methyl group of the aglycone of 2,3-unsaturated glycosides with configuration (R) absorbs at a slightly lower field (d 1.32 ppm). 13 The products 7a-e produced an anomeric proton at δ 5.04-5.17 ppm as a singlet indicating the axial configuration of the 1-methyl-[3-(aryl)-1,2,4-oxadiazol-5-yl]-propyl group. Hence, it is concluded that compounds 7a-e are exclusively the α-anomer.
The 13 C NMR spectrum of the compounds 7a-e exhibits between 18 and 21 carbon atoms, all approximately equal in height; several of them have characteristic chemical shifts. The presence of a peak between 91.5-94.6 ppm is typical of anomeric carbons of glucosides (C-1); additional peaks at 129. 4, 128.3, 67.5, 64.7 and, 64.6 ppm support the idea that the compound contains α-glucopyranose moiety. A DEPT spectrum reveals that the peaks lathes 179. , and 131.4-141.8 (C-1') ppm lack protons, those at 23.9 (C-9), 34. 6 and 65.8 (C-6) ppm are methylene groups, and all other carbons bear one hydrogen.
The compound 7b, which had better crystals, was subjected to X-ray crystallography. These crystals had the configuration (S) at the carbon atom containing the methyl group in the aglycone moiety. The crystallographic data provided precise information regarding the configuration (at C-11). As expected, the configurations at C(12), C(13) and C(14) are (R), (S) and (S), respectively. The ortep diagram is shown in Figure 3 .
Excellent enantiopurity of each of the generated alcohols 5a-e was attained (>90% ee).
1 H NMR spectroscopy in the presence of the chiral shift reagent europium tris[3-heptafluoropropylhydroxymethylene)-(+)-camphorate, conducted on both racemic and enantiopure samples, determined that each of the products isolated 5a-e was enantiopure, demonstrating that baker's yeast was capable of effecting selective reduction. Thus, the compounds 5a-e can fit into the active site of the yeast reductase to facilitate hydride delivery to the carbonyl group.
The results of the baker's yeast reduction of these compounds are shown in the Table 1. Since the spectra of both (+)-and (-)-4-[3-(aryl)-1,2,4-oxadiazol-5-yl]-butanols are identical, the usual chemical shift reagent would not help our analysis. However, if one uses a chemical shift reagent that is itself chiral, one can begin to distinguish the two enantiomers by their NMR spectra. The two enantiomers, which are chiral, will interact differently with the chiral shift reagent. The complexes formed from the (R) and (S) isomers and with (+)-camphor containing the shift reagent will be diastereomers. Diastereomers usually have different physical properties, and the NMR spectra are no exception. The two complexes will be formed with slightly differing geometries. Although the effect is small, it is large enough to begin to see differences in the NMR spectra of the two enantiomers. In particular, the The crystallographic data supported the attributions made from the proton magnetic resonance spectroscopy. All distances and angles for (7b) are consistent with the expected values. The crystal data and structure refinement for (S)-Methyl-[3-(o-tolyl)-1,2,4-oxadiazol-5-yl] propyl 4,6-di-O-acetyl-2,3-dideoxy-α-d-erythro-hex-2-enopyranoside (7b) is shown in Table 2 . 
